GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (XTAE:CLGN) » Definitions » Net Cash per Share

CollPlant Biotechnologies (XTAE:CLGN) Net Cash per Share : ₪0.34 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CollPlant Biotechnologies Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). CollPlant Biotechnologies's Net Cash per Share for the quarter that ended in Mar. 2024 was ₪0.34.

The historical rank and industry rank for CollPlant Biotechnologies's Net Cash per Share or its related term are showing as below:

XTAE:CLGN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.53   Med: 3.7   Max: 5.55
Current: 2.53

During the past 12 years, the highest Price-to-Net-Cash Ratio of CollPlant Biotechnologies was 5.55. The lowest was 2.53. And the median was 3.70.

XTAE:CLGN's Price-to-Net-Cash is ranked better than
54.18% of 862 companies
in the Biotechnology industry
Industry Median: 3.835 vs XTAE:CLGN: 2.53

CollPlant Biotechnologies Net Cash per Share Historical Data

The historical data trend for CollPlant Biotechnologies's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies Net Cash per Share Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.06 0.73 0.47 0.41

CollPlant Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.33 0.47 0.41 0.34

Competitive Comparison of CollPlant Biotechnologies's Net Cash per Share

For the Biotechnology subindustry, CollPlant Biotechnologies's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's Price-to-Net-Cash falls into.



CollPlant Biotechnologies Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

CollPlant Biotechnologies's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(99.42-21.566-0)/190.536
=0.41

CollPlant Biotechnologies's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(86.565-21.789-0)/190.536
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CollPlant Biotechnologies  (XTAE:CLGN) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


CollPlant Biotechnologies Net Cash per Share Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies (XTAE:CLGN) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.

CollPlant Biotechnologies (XTAE:CLGN) Headlines

From GuruFocus